CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Option exercise CEO acquired 16,535 shares (option exercise)
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Open-market buy Director bought 5,000 shares at $1.55 ($7,750)
- 4 Grant or award SVP, Chief Scientific Officer acquired 60,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- S-8 Other Securities Offered to Employees in Benefit Plans
- 8-K Event Results of operations
- 10-K Report Annual Report
- 10-K/A Report 10-K/A
- 4 Open-market sale SVP, Finance and Accounting sold 516 shares at $1.98 ($1,021)
- 4 Open-market sale CEO sold 7,121 shares at $1.88 ($13,391)
- 4 Open-market sale Chief Financial Officer sold 1,748 shares at $1.98 ($3,459)
- 4 Open-market sale General Counsel sold 2,037 shares at $1.98 ($4,031)
- 4 Open-market sale Chief Financial Officer sold 1,477 shares at $1.98 ($2,923)
- 4 Open-market sale EVP, Chief Development Officer sold 4,257 shares at $1.98 ($8,425)
Page 12 of 41 · 801 filings